To Russia began to deliver the vaccine "Sputnik of V" manufactured in South Korea

2020

Start of supply of vaccine from COVID-19 "Sputnik of V" in the Russian Federation manufactured in South Korea

In Russia began to deliver the vaccine against a coronavirus COVID-19 "Satellite V", made century To South Korea. The Asiana Airline delivered the first batch of medicine in Moscow December 25, 2020, the second — on December 29. In January the 2021st is expected by supply of vaccine to other countries.

According to the Yonhap agency, is engaged in production by "Sputnik of V" in South Korea the Hankook Korus Pharm company entering into the GL Rapha group with which earlier the Russian Direct Investment Fund (RDIF) signed the agreement on production of vaccines.

To Russia began to deliver the vaccine "Sputnik of V" manufactured in South Korea

At the beginning of December, 2020 the head of department of GL Rapha public relations Kim Gui Yong in a conversation with RIA Novosti reported that the company conducted negotiations with all necessary bodies in South Korea concerning obtaining all permissions for production and storage of vaccine.

There are no big problems as vaccine is anyway intended not for South Korea. All amount contracted at the moment is intended for the Middle East, – he explained.

According to Kim Gui of Yong, GL Rapha is ready to provide additional production volumes. He said that at first vaccine will be produced in the frozen type allowing storage at-18 degrees, however, if further the Russian side transfers the companies of data on production of the lyophilized type (storage at +2 ~ 8 degrees), then GL Rapha will be able to make both types.

If to compare, for example, with vaccine of Pfizer which is stored at-70 degrees she demands special packaging and specialized transportation. Besides, after extraction from a special container vaccine is effective only within half an hour. Therefore it is complex both in transportation, and in use. In case of the vaccine "Sputnik of V" storage is possible at-18 degrees therefore they can be transported in normal isothermal containers. It can be also used during rather bigger time therefore in terms of logistics is more convenient, – Kim Gui Yong said.[1][1][2][3]

The agreement GL Rapha and RDIF on production of 150 million fur-coats of vaccine from COVID-19

On November 13, 2020 it was announced signing of the contract between the Russian Direct Investment Fund (RDIF) and GL Rapha. Under the terms of the agreement, the South Korean biopharmaceutical company will annually produce 150 million doses of vaccines against COVID-19 coronavirus.

Production of the Russian medicine in South Korea will begin in December, 2020, and deliveries — in January of the 2021st. The released GL Rapha will go for export to the different countries. Where exactly vaccine will be delivered, on November 13, 2020 it is not reported.

South Korea will produce 150 million doses of the vaccine "Sputnik of V" against a coronavirus for export

The CEO of RDIF Kirill Dmitriyev expressed the need "develop the international cooperation and partnership for ensuring enough the vaccine "Sputnik of V" and satisfaction of the international demand".

According to RDIF, by November 13, 2020 requests for acquisition more than 1.2 billion doses of the vaccines "Sputnik of V" from more than 50 countries arrived. Vaccine for deliveries to foreign markets will be manufactured by the international partners of RDIF in India, Brazil, China, South Korea and other countries. Also there take place clinical trials of vaccine in Belarus, the UAE, Venezuela, India and some other countries. The existing arrangements of RDIF with the international partners will allow to produce outside Russia 500 million doses of the vaccine "Sputnik of V" a year, RDIF notes. By November 13 the fund considers additional requests from some countries and the companies on further increase abroad in production capacities.

The press service of World Health Organization reported that "Sputnik of V" can enter the list of the recommended vaccines for the emergency use. For this purpose the Russian medicine should undergo testing for compliance to necessary requirements. The request to WHO was sent by Research Center of N.F. Gamalei which developed vaccine.^[4]

Notes